Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib + nivolumab
- Development stage
- Unknown
- Lead developer
- Exelixis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cabozantinib + nivolumab is a fixed combination regimen of two distinct drugs used for the treatment of advanced renal cell carcinoma (RCC). Cabozantinib is an oral small molecule tyrosine kinase inhibitor that targets multiple kinases, including vascular endothelial growth factor receptors (VEGFRs), MET, and AXL, thereby inhibiting tumor angiogenesis and proliferation. Nivolumab is a monoclonal antibody immune checkpoint inhibitor targeting programmed death 1 (PD-1) receptor on T cells, enhancing anti-tumor immune responses. The combination leverages both direct anti-tumor effects via kinase inhibition and immunomodulation to improve clinical outcomes in patients with advanced RCC. This regimen has demonstrated significant improvements in progression-free survival, overall survival, and objective response rate compared to sunitinib in first-line therapy for advanced RCC[1][2][3][4][5][8].
- Brand names
- Cabometyx + Opdivo
- Other names
- cabozantinib plus nivolumabNIVO + CABOOpdivo plus Cabometyx
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)AXL (AXL receptor tyrosine kinase)TEK (Tie2)RET (Rearranged during transfection receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on cabozantinib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib + nivolumab.